Pharmacy

Hospitals realized a 30% cut in reimbursement after an appeals court ruling upheld the Trump Administration decision.

This week's top stories include Scripps being hit with four class-action lawsuits, AWS creating a new accelerator, and five Blue Cross Blue Shield plans launching a for-profit company focused on lowering drug prices.

The program will first be made eligible to patients taking the biologic called Remicade, which treats inflammatory conditions.

The goal of the new organization is to improve medication affordability, clinical outcomes and medication experiences.

The settlement is the “first and largest in the country secured by a state attorney general against a pharmacy benefit manager,” Ohio AG says.

The intent is to respond to the urgent need for antivirals by spurring the availability of medicines to prevent serious illness.

This week's top stories include Hims & Hers expanding beyond the U.S. market with the acquisition of British personalized health company Honest Health and the AHA asking Express Scripts to rescind its 340B claims reporting policy.

The judgement nixes HHS' motion and allows AstraZeneca's lawsuit to continue, with a judge saying the statute is open to interpretation.

The change, said Express Scripts, was made in the spirit of "greater transparency" and was not intended to alter reimbursement.

The first CivicaScript generic medicines will be available as early as 2022, through retail and mail-order pharmacies.